Connect with us

Government

Why China Sucks: It’s A Beta-Test For The New World Order

Why China Sucks: It’s A Beta-Test For The New World Order

Authored by Brandon Smith via Alt-Market.us,

For over a decade there has been an…

Published

on

Why China Sucks: It's A Beta-Test For The New World Order

Authored by Brandon Smith via Alt-Market.us,

For over a decade there has been an open globalist obsession with the Chinese governmental model – A love affair, if you will. Many top proponents of global centralization including Henry Kissinger and George Soros have praised China in the past and hinted that the communist country is burgeoning into a major player within the New World Order. Soros expressed this exact sentiment way back in 2009, around the time that China began courting the IMF and issuing trillions in Yuan based treasury debt in order to join their global currency initiative.

Several years later, China was inducted into the IMF’s Special Drawing Rights basket. The CCP now avidly supports the creation of a new global currency system with the IMF in control.

This is a reality I have been writing about for many years: China does NOT stand in opposition to global centralization under the control of western oligarchs. All they want is a prominent seat at the table when the “Great Reset” kicks off and total centralization begins. But the above information only suggests an economic relationship between China and the globalists. Does the alliance go even further than that?

Recently, Klaus Schwab of the World Economic Forum gave an interview to the Chinese government controlled CGTN at the APEC Summit. In that interview, Schwab praises China as a role model for many other nations. This might shock some people considering China’s economy is faltering, with their global exports plunging in 2022 and their housing market in shambles. This decline is in large part due to global stagflation, but also due to their insane “zero covid” policy which has kept the nation under pandemic lockdown for years.

Remember all those covid cultists who were cheering for China last year? Remember when they claimed that China was a perfect example on why lockdowns are necessary and proof that they work? Yeah, those people were morons.

China’s economy is now in freefall with their manufacturing base under extreme stress from the mandates. Furthermore, it would appear that the Chinese populace is finally fed up with the draconian conditions and are rising up in revolt.

In the video below, protests erupt at Foxconn’s flagship iPhone plant in China after workers marched out of the factory. They had been held there in quarantine against their will with poor working conditions and little food.

The Chinese government sent hazmat clad troops to put down the rebellion while stomping protesters into the ground. Take note and remember this video when you hear about Apple’s hostility to Elon Musk’s free speech policies on Twitter – Apple loves authoritarianism, as do all globalist run corporations.

China continues to terrorize the citizenry with secret police visits to vocal dissenters and fleets of drones hovering above city streets monitoring foot traffic and blaring propaganda messages. Some drones even spray unknown chemicals across entire city blocks. In the meantime, China has fully implemented digital vaccine passports systems tied to public venues and retail stores. You cannot function in a major Chinese city without an up-to-date vaccine passport or a negative covid test taken every couple of weeks.

All of these events and conditions are often treated as disconnected or coincidentally associated. No one is asking the right questions. The big question being WHY? Why is the Chinese government sabotaging its own economy with lockdowns and oppressing the population to the point of open revolt (a rarity among the normally subservient Chinese people). Why keep the lockdowns going when it is clear to the rest of the world that the pandemic is over and that the lockdowns and masks never worked to begin with?

I would ask CCP officials a simple question that many of us in America also asked our own government a over a year ago: If the vaccines work, why enforce mandates and lockdowns? If it’s because the vaccines don’t work, then why try to force the population to take the jab? Beyond that, if the masks and lockdowns work, then why is China facing yet another supposed covid infection wave?

Obviously the CCP does not care about the well being of the average Chinese citizen. There is no logic to anything they are doing, just as there was no logic to anything Biden, Fauci and the CDC were doing in the US. The difference is, Americans were able to force the globalists in the US to abandon their mandate agenda, likely because we are heavily armed and they realized too many of us were non-compliant. In China, there is no civilian militia equivalent.

The country was a dystopia before, now it is something different – It is an experiment in technocratic tyranny that is being taken to the extreme. China is willing to starve, arrest, beat and even kill people who they claim they are trying to protect from the virus.

It is no mistake that nearly every policy China is implementing is a direct copy of policies suggested by the WEF and institutions like the Imperial College of London back in 2020 at the start of the outbreak. The globalists argued that “we are not going back to normal” and that the public would have to sacrifice many of our freedoms in order to stop the pandemic. In reality, none of their policies were effective in stopping the spread, but they were very effective at suppressing the populace. And in the case of China, nothing did ever go back to normal.

The unspoken rationale, in my view, connects directly back to China’s long term relationship to the globalists and their desire to be a part of the New World Order, also referred to as the “multipolar world order”, the 4th Industrial Revolution, the Great Reset and a dozen other names. If you want to know the real globalist vision for the future, take a look at China today and then multiply the pain and suffering another hundred fold. China is a beta test.

Perhaps it’s a test to see what level of tyranny people are willing to endure. Maybe a test of the functionality of different surveillance systems and control mechanisms. Maybe a practice run for the inevitable riots and rebellion that would occur in numerous countries and the best way to deal with them. Globalists like Klaus Schwab are not only interest in China as an economic role model, he sees China as a societal role model for much of the west, with some tweaks here and there.

The problem for the establishment is that if there are visible examples of freedom despite covid, then other nations will start to question the necessity of their own lockdowns. Even the Chinese people are starting to fight back. They can’t implement their NWO one country at a time, they will have to oppress many countries at once.

As I have been saying for the past year to some of the more nihilistic people in the liberty movement who think all it lost, understand that you are lucky to be living in the US right now and you should be thankful for the millions of conservatives that actively and vocally refused to comply with the mandates and vaccines. They saved the country from greater tyranny. If the globalists had got what they really wanted, we would look a lot like China right now.

We hovered close to that black sun and danced with the devil, but we are not beaten.

As it stands, China continues to represent a model of authoritarian dreams; a research study in mass psychological torture. Far from being a counter-point to the globalists, it is actually a globalist work in progress. Watch what happens there closely, because the evils perpetrated there will eventually be attempted here at home.

*  *  *

If you would like to support the work that Alt-Market does while also receiving content on advanced tactics for defeating the globalist agenda, subscribe to our exclusive newsletter The Wild Bunch Dispatch.  Learn more about it HERE.

Tyler Durden Fri, 12/02/2022 - 23:55

Read More

Continue Reading

Government

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide…

Published

on

Glimpse Of Sanity: Dartmouth Returns Standardized Testing For Admission After Failed Experiment

In response to the virus pandemic and nationwide Black Lives Matter riots in the summer of 2020, some elite colleges and universities shredded testing requirements for admission. Several years later, the test-optional admission has yet to produce the promising results for racial and class-based equity that many woke academic institutions wished.

The failure of test-optional admission policies has forced Dartmouth College to reinstate standardized test scores for admission starting next year. This should never have been eliminated, as merit will always prevail. 

"Nearly four years later, having studied the role of testing in our admissions process as well as its value as a predictor of student success at Dartmouth, we are removing the extended pause and reactivating the standardized testing requirement for undergraduate admission, effective with the Class of 2029," Dartmouth wrote in a press release Monday morning. 

"For Dartmouth, the evidence supporting our reactivation of a required testing policy is clear. Our bottom line is simple: we believe a standardized testing requirement will improve—not detract from—our ability to bring the most promising and diverse students to our campus," the elite college said. 

Who would've thought eliminating standardized tests for admission because a fringe minority said they were instruments of racism and a biased system was ever a good idea? 

Also, it doesn't take a rocket scientist to figure this out. More from Dartmouth, who commissioned the research: 

They also found that test scores represent an especially valuable tool to identify high-achieving applicants from low and middle-income backgrounds; who are first-generation college-bound; as well as students from urban and rural backgrounds.

All the colleges and universities that quickly adopted test-optional admissions in 2020 experienced a surge in applications. Perhaps the push for test-optional was under the guise of woke equality but was nothing more than protecting the bottom line for these institutions. 

A glimpse of sanity returns to woke schools: Admit qualified kids. Next up is corporate America and all tiers of the US government. 

Tyler Durden Mon, 02/05/2024 - 17:20

Read More

Continue Reading

International

Four burning questions about the future of the $16.5B Novo-Catalent deal

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.
Beyond spending billions of dollars to expand…

Published

on

To build or to buy? That’s a classic question for pharma boardrooms, and Novo Nordisk is going with both.

Beyond spending billions of dollars to expand its own production capacity for its weight loss drugs, the Danish drugmaker said Monday it will pay $11 billion to acquire three manufacturing plants from Catalent. It’s part of a broader $16.5 billion deal with Novo Holdings, the investment arm of the pharma’s parent group, which agreed to acquire the contract manufacturer and take it private.

It’s a big deal for all parties, with potential ripple effects across the biotech ecosystem. Here’s a look at some of the most pressing questions to watch after Monday’s announcement.

Why did Novo do this?

Novo Holdings isn’t the most obvious buyer for Catalent, particularly after last year’s on-and-off M&A interest from the serial acquirer Danaher. But the deal could benefit both Novo Holdings and Novo Nordisk.

Novo Nordisk’s biggest challenge has been simply making enough of the weight loss drug Wegovy and diabetes therapy Ozempic. On last week’s earnings call, Novo Nordisk CEO Lars Fruergaard Jørgensen said the company isn’t constrained by capital in its efforts to boost manufacturing. Rather, the main challenge is the limited amount of capabilities out there, he said.

“Most pharmaceutical companies in the world would be shopping among the same manufacturers,” he said. “There’s not an unlimited amount of machinery and people to build it.”

While Novo was already one of Catalent’s major customers, the manufacturer has been hamstrung by its own balance sheet. With roughly $5 billion in debt on its books, it’s had to juggle paying down debt with sufficiently investing in its facilities. That’s been particularly challenging in keeping pace with soaring demand for GLP-1 drugs.

Novo, on the other hand, has the balance sheet to funnel as much money as needed into the plants in Italy, Belgium, and Indiana. It’s also struggled to make enough of its popular GLP-1 drugs to meet their soaring demand, with documented shortages of both Ozempic and Wegovy.

The impact won’t be immediate. The parties expect the deal to close near the end of 2024. Novo Nordisk said it expects the three new sites to “gradually increase Novo Nordisk’s filling capacity from 2026 and onwards.”

As for the rest of Catalent — nearly 50 other sites employing thousands of workers — Novo Holdings will take control. The group previously acquired Altasciences in 2021 and Ritedose in 2022, so the Catalent deal builds on a core investing interest in biopharma services, Novo Holdings CEO Kasim Kutay told Endpoints News.

Kasim Kutay

When asked about possible site closures or layoffs, Kutay said the team hasn’t thought about that.

“That’s not our track record. Our track record is to invest in quality businesses and help them grow,” he said. “There’s always stuff to do with any asset you own, but we haven’t bought this company to do some of the stuff you’re talking about.”

What does it mean for Catalent’s customers? 

Until the deal closes, Catalent will operate as a standalone business. After it closes, Novo Nordisk said it will honor its customer obligations at the three sites, a spokesperson said. But they didn’t answer a question about what happens when those contracts expire.

The wrinkle is the long-term future of the three plants that Novo Nordisk is paying for. Those sites don’t exclusively pump out Wegovy, but that could be the logical long-term aim for the Danish drugmaker.

The ideal scenario is that pricing and timelines remain the same for customers, said Nicole Paulk, CEO of the gene therapy startup Siren Biotechnology.

Nicole Paulk

“The name of the group that you’re going to send your check to is now going to be Novo Holdings instead of Catalent, but otherwise everything remains the same,” Paulk told Endpoints. “That’s the best-case scenario.”

In a worst case, Paulk said she feared the new owners could wind up closing sites or laying off Catalent groups. That could create some uncertainty for customers looking for a long-term manufacturing partner.

Are shareholders and regulators happy? 

The pandemic was a wild ride for Catalent’s stock, with shares surging from about $40 to $140 and then crashing back to earth. The $63.50 share price for the takeover is a happy ending depending on the investor.

On that point, the investing giant Elliott Investment Management is satisfied. Marc Steinberg, a partner at Elliott, called the agreement “an outstanding outcome” that “clearly maximizes value for Catalent stockholders” in a statement.

Elliott helped kick off a strategic review last August that culminated in the sale agreement. Compared to Catalent’s stock price before that review started, the deal pays a nearly 40% premium.

Alessandro Maselli

But this is hardly a victory lap for CEO Alessandro Maselli, who took over in July 2022 when Catalent’s stock price was north of $100. Novo’s takeover is a tacit acknowledgment that Maselli could never fully right the ship, as operational problems plagued the company throughout 2023 while it was limited by its debt.

Additional regulatory filings in the next few weeks could give insight into just how competitive the sale process was. William Blair analysts said they don’t expect a competing bidder “given the organic investments already being pursued at other leading CDMOs and the breadth and scale of Catalent’s operations.”

The Blair analysts also noted the companies likely “expect to spend some time educating relevant government agencies” about the deal, given the lengthy closing timeline. Given Novo Nordisk’s ascent — it’s now one of Europe’s most valuable companies — paired with the limited number of large contract manufacturers, antitrust regulators could be interested in taking a close look.

Are Catalent’s problems finally a thing of the past?

Catalent ran into a mix of financial and operational problems over the past year that played no small part in attracting the interest of an activist like Elliott.

Now with a deal in place, how quickly can Novo rectify those problems? Some of the challenges were driven by the demands of being a publicly traded company, like failing to meet investors’ revenue expectations or even filing earnings reports on time.

But Catalent also struggled with its business at times, with a range of manufacturing delays, inspection reports and occasionally writing down acquisitions that didn’t pan out. Novo’s deep pockets will go a long way to a turnaround, but only the future will tell if all these issues are fixed.

Kutay said his team is excited by the opportunity and was satisfied with the due diligence it did on the company.

“We believe we’re buying a strong company with a good management team and good prospects,” Kutay said. “If that wasn’t the case, I don’t think we’d be here.”

Amber Tong and Reynald Castañeda contributed reporting.

Read More

Continue Reading

International

Petrina Kamya, Ph.D., Head of AI Platforms at Insilico Medicine, presents at BIO CEO & Investor Conference

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb….

Published

on

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

Credit: Insilico Medicine

Petrina Kamya, PhD, Head of AI Platforms and President of Insilico Medicine Canada, will present at the BIO CEO & Investor Conference happening Feb. 26-27 at the New York Marriott Marquis in New York City. Dr. Kamya will speak as part of the panel “AI within Biopharma: Separating Value from Hype,” on Feb. 27, 1pm ET along with Michael Nally, CEO of Generate: Biomedicines and Liz Schwarzbach, PhD, CBO of BigHat Biosciences.

The session will look at how the latest artificial intelligence (AI) tools – including generative AI and large language models – are currently being used to advance the discovery and design of new drugs, and which technologies are still in development. 

The BIO CEO & Investor Conference brings together over 1,000 attendees and more than 700 companies across industry and institutional investment to discuss the future investment landscape of biotechnology. Sessions focus on topics such as therapeutic advancements, market outlook, and policy priorities.

Insilico Medicine is a leading, clinical stage AI-driven drug discovery company that has raised over $400m in investments since it was founded in 2014. Dr. Kamya leads the development of the Company’s end-to-end generative AI platform, Pharma.AI from Insilico’s AI R&D Center in Montreal. Using modern machine learning techniques in the context of chemistry and biology, the platform has driven the discovery and design of 30+ new therapies, with five in clinical stages – for cancer, fibrosis, inflammatory bowel disease (IBD), and COVID-19. The Company’s lead drug, for the chronic, rare lung condition idiopathic pulmonary fibrosis, is the first AI-designed drug for an AI-discovered target to reach Phase II clinical trials with patients. Nine of the top 20 pharmaceutical companies have used Insilico’s AI platform to advance their programs, and the Company has a number of major strategic licensing deals around its AI-designed therapeutic assets, including with Sanofi, Exelixis and Menarini. 

 

About Insilico Medicine

Insilico Medicine, a global clinical stage biotechnology company powered by generative AI, is connecting biology, chemistry, and clinical trials analysis using next-generation AI systems. The company has developed AI platforms that utilize deep generative models, reinforcement learning, transformers, and other modern machine learning techniques for novel target discovery and the generation of novel molecular structures with desired properties. Insilico Medicine is developing breakthrough solutions to discover and develop innovative drugs for cancer, fibrosis, immunity, central nervous system diseases, infectious diseases, autoimmune diseases, and aging-related diseases. www.insilico.com 


Read More

Continue Reading

Trending